Coherus Biosciences | CHRS - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
AbbVie USD 7.61B 2.04B 2026-06
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Akebia Therapeutics USD -11.24M 12.39M 2025-12
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amarin USD -852K 7.26M 2025-12
Amgen USD 2.08B 570M 2026-03
Baxter International USD 362M 368M 2026-06
Biogen USD 647.3M 269.6M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.85B 583.8M 2026-03
Fujifilm JPY 104.44B 4.16B 2026-03
Gilead Sciences USD -7.53B 10.11B 2026-06
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Merck USD -3.53B 6.95B 2026-03
Myriad Genetics USD 4.6M 3.4M 2025-12
Pacira USD 5M 4.43M 2026-03
Perrigo USD 105.4M 513.9M 2026-06
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Teva Pharmaceutical Industries USD -455M 1.21B 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06
Xencor USD -21.92M 106.72M 2026-06
Zoetis USD 758M 3M 2026-03